诸侯快讯ok1133-诸侯快讯网-诸侯快讯手机版

About Bio-s

Company Overview

R&D Services

Technology transfer

Technology Platforms

Innovative Technology

Traditional Chinese Medicine and Natural Medicine

Nervous System Platform

Animal Health Product R&D Center

clinical research platform

Impurity Research Platform

Fine Particle Taste Masking

Sustained＆Controlled Release Preparation

Transdermal Drug Delivery

Inhalation Preparation

Projects under research

Impurity customization

Impurity customization

Impurity control substancen

News

Industry information

Pharmaceutical regulations

Pharmaceutical regulations

Reference preparation catalog

Investor relations

Company announcements

诸侯快讯ok1133医药：2024第一季度报告全文

诸侯快讯ok1133医药：2023年第三季度报告全文

诸侯快讯ok1133医药：2023年半年度报告全文

诸侯快讯ok1133医药：2023年第一季度报告全文

诸侯快讯ok1133医药：2022年年度报告全文

诸侯快讯ok1133医药：2022年第三季度报告全文

诸侯快讯ok1133医药：2022年半年度报告全文

诸侯快讯ok1133医药：2022年半年度报告摘要

诸侯快讯ok1133医药：2022年第一季度报告全文

诸侯快讯ok1133医药：2021年年度报告摘要

Financial news

诸侯快讯ok1133医药（301096）查看股票信息

Investor contact

Investor contact

Email:stock@hzbio-s.com

Tel：0571-87923909
传真：0571-87923909

You are welcome to contact us via the online form below.

We will answer your inquiries in various ways, and jointly provide customized professional consultation and solutions for your research and development needs.

What information and information do you want to know?